Infliximab for the treatment of resistant oral ulcers in Behçet's disease: a case report and review of the literature
- PMID: 17949561
Infliximab for the treatment of resistant oral ulcers in Behçet's disease: a case report and review of the literature
Abstract
Recurrent oral and genital ulceration of Behçet's disease can be very distressing. Usually they are responsive to treatment with topical steroids, local anesthetics, oral colchicine and in severe cases steroids and even immuno-suppressive medications such as azathioprine, methotrexate and thalidomide. We describe a case of Behçet's syndrome in a 48-year old woman whose oral ulcers were resistant to a wide range of topical and systemic treatments and remained unchanged for 7 weeks. Administration of a single dose of infliximab resulted in complete remission and recovery of the mouth aphtae within 7 days. We also review the current English medical literature and summarize 5 more cases where anti-TNF agents were used in the treatment of recalcitrant orogenital ulceration in Behçet's disease.
Similar articles
-
Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab.Rheumatology (Oxford). 2001 Apr;40(4):473-4. doi: 10.1093/rheumatology/40.4.473. Rheumatology (Oxford). 2001. PMID: 11312390 No abstract available.
-
Successful treatment of recalcitrant genital ulcers of Behçet's disease with adalimumab after failure of infliximab and etanercept.Clin Exp Rheumatol. 2009 Mar-Apr;27(2 Suppl 53):S112. Clin Exp Rheumatol. 2009. PMID: 19796550 No abstract available.
-
[Behçet's disease - Infliximab in the treatment of mucocutaneous manifestations].Acta Reumatol Port. 2009 Oct-Dec;34(4):633-40. Acta Reumatol Port. 2009. PMID: 20852576 Portuguese.
-
[Behçet's disease].Ned Tijdschr Tandheelkd. 2008 Jun;115(6):340-5. Ned Tijdschr Tandheelkd. 2008. PMID: 18618988 Review. Dutch.
-
Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.Gut Liver. 2018 Nov 15;12(6):623-632. doi: 10.5009/gnl17462. Gut Liver. 2018. PMID: 29788675 Free PMC article. Review.
Cited by
-
Update on the therapy of Behçet disease.Ther Adv Chronic Dis. 2014 May;5(3):112-34. doi: 10.1177/2040622314523062. Ther Adv Chronic Dis. 2014. PMID: 24790727 Free PMC article. Review.
-
Tumor necrosis factor alpha (TNF-α) blockage reduces acute inflammation and delayed wound healing in oral ulcer of rats.Inflammopharmacology. 2022 Oct;30(5):1781-1798. doi: 10.1007/s10787-022-01046-3. Epub 2022 Aug 10. Inflammopharmacology. 2022. PMID: 35948810
-
Is Optimal Management of Recurrent Aphthous Stomatitis Possible? A Reality Check.J Clin Diagn Res. 2016 Oct;10(10):ZE08-ZE13. doi: 10.7860/JCDR/2016/19519.8643. Epub 2016 Oct 1. J Clin Diagn Res. 2016. PMID: 27891490 Free PMC article. Review.
-
Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet's disease.Rheumatol Int. 2011 Aug;31(8):1097-9. doi: 10.1007/s00296-009-1276-x. Epub 2009 Dec 11. Rheumatol Int. 2011. PMID: 20012049
-
The Efficacy of Medium- to Long-term Anti-TNF-α Antibody-based Maintenance Therapy in Behçet's Disease Patients with Intestinal Lesions.Intern Med. 2020;59(19):2343-2351. doi: 10.2169/internalmedicine.5000-20. Epub 2020 Oct 1. Intern Med. 2020. PMID: 32999263 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical